Non-alcoholic fatty liver disease and its relationship with autonomic neuropathy in patients with type 2 diabetes mellitus

• Nadezhda A. Soldatenkova
• Irina V. Gurieva
• Natalya V. Mazurchik

Abstract

Currently, non-alcoholic fatty liver disease (NAFLD) occupies a leading position in the list of the most common liver diseases. According to a number of studies, one of the reasons for the development of NAFLD may be autonomic neuropathy. Few studies have been conducted on this problem, but the topic of the correlation between autonomic neuropathy and NAFLD has not been sufficiently studied. As a result, the purpose of this article will be to consider autonomic neuropathy as one of the possible etiological factors of the development of NAFLD.

In 2020, a panel of international experts published a consensus suggesting a new interpretation of the disease, a change in the criteria for diagnosing NAFLD. The experts introduced a new adaptive term “metabolic associated fatty liver disease”, which, according to the consensus authors, allowed to emphasize the systemic and multifactorial nature of the disease.

Keywords:metabolically associated fatty liver disease; non-alcoholic fatty liver disease; autonomic neuropathy

References

1. URL: https://www.who.int/ru

2. Ludwig J., Viggiano T.R., McGill D.B., Oh B.J. Nonalocogolic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980; 55 (7): 434–8.

3. Eslam M., Newsome P.N., Sarin S.K. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020; 73 (1): 202–9. DOI: https://doi.org/10.1016/j.jhep.2020.03.039

4. Ministry of Health of the Russian Federation. Clinical recommendations «Non-alcoholic fatty liver disease in adults». URL: http://cr.minzdrav.gov.ru/schema/748_1 (in Russian)

5. Le M.H., Yeo Y.H., Li X. et al. 2019 Global NAFLD Prevalence: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022; 20 (12): 2809–17.e28. DOI: https://doi.org/10.1016/j.cgh.2021.12.002

6. Ivashkin B.T., Drapkina O.M., Maev I.V., et al. Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study results. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii [Russian Journal of Gastroenterology, Hepatology, Coloproctology]. 2015; 25 (6): 31–41. (in Russian)

7. Younossi Z.M., Golabi P., Avila de L., et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019; 71 (4): 793–801. DOI: https://doi.org/10.1016/j.jhep.2019.06.021

8. Smith G.I., Shankaran M., Yoshino M., et al. Insulin resistance drives hepatic de novo lipogenesis in nonalcogolic fatty liver disease. Clinical trial. J Clin Invest. 2020; 130 (3): 1453–60. DOI: https://doi.org/10.1172/JCI134165

9. Bozzetto L., Annuzzi G., Ragucci M., et al. Insulin resistance, postprandial GLP-1 and adaptive immunity are the main predictors of NAFLD in a homogeneous population at high cardiovascular risk. Randomized controlled trial. Nutr Metab Cardiovasc Dis. 2016; 26 (7): 623–9. DOI: https://doi.org/10.1016/j.numecd.2016.01.011

10. Zaharia O.P., Strassburger K., Strom A., et al. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol. 2019; 7 (9): 684–94. DOI: https://doi.org/10.1016/S 2213-8587(19)30187-1

11. Obukhova L.A. Autonomous innervation of organs. Tutorial. In: Novosibirsk State University Novosibirsk, 2020: 34 p. (in Russian)

12. Ermakova N.N. Pathogenetic substantiation of the use of sympatholytic in the regulation of stem cells and stimulation of regeneration in experimental pathology: Diss. Tomsk, 2022: 297 p. (in Russian)

13. Sabath E., Báez-Ruiz A., Buijs R.M. Non-alcoholic fatty liver disease as a consequence of autonomic imbalance and circadian desynchronization. Review. Obes Rev. 2015; 16 (10): 871–82. DOI: https://doi.org/10.1111/obr.12308

14. Carreno F.R., Seelaender M.C. Liver denervation affects hepatocyte mitochondrial fatty acid transport capacity. Cell Biochem Funct. 2004; 22: 9–17.

15. Bruinstroop E., Pei L., Ackermans M.T., et al. Hypothalamic neuropeptide Y (NPY) controls hepatic VLDL-triglyceride secretion in rats via the sympathetic nervous system. Diabetes. 2012; 61:1043–50.

16. Rasouli M., Mosavi-Mehr M., Tahmouri H. Liver denervation increases the levels of serum triglyceride and cholesterol via increases in the rate of VLDL secretion. Clin Res Hepatol Gastroenterol. 2012; 36: 60–5.

17. Houghton D., Zalewski P., Hallsworth K., et al. The degree of hepatic steatosis associates with impaired cardiac and autonomic function. J Hepatol. 2019; 70 (6): 1203–13. DOI: https://doi.org/10.1016/j.jhep.2019.01.035

18. Liu Y.C., Hung C.S., Wu Y.W., Lee Y.C., et al. Influence of non-alcoholic fatty liver disease on autonomic changes evaluated by the time domain, frequency domain, and symbolic dynamics of heart rate variability. PLoS One. 2013; 8 (4): e61803. DOI: https://doi.org/10.1371/journal.pone.0061803

19. Musso G., Cassader M., Rosina F., Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Review. Diabetologia. 2012; 55 (4): 885–904. DOI: https://doi.org/10.1007/s00125-011-2446-4

20. Vilar-Gomez E., Martinez-Perez Y., Calzadilla-Bertot L., et al. Weight loss via lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015; 149: 367–78.e5.

21. Chalasani N., Younossi Z., Lavine J.E., et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018; 67 (1): 328–57. DOI: https://doi.org/10.1002/hep.29367

22. Adams L.A., Sanderson S., Lindor K.D., et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol. 2005; 42: 132–8.

23. Sanyal A.J., Friedman S.L., McCullough A.J., et al. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases – U.S. Food and Drug Administration Joint Workshop. Practice Guideline. Hepatology. 2015; 61 (4): 1392–405. DOI: https://doi.org/10.1002/hep.27678

24. Neuschwander-Tetri B.A., Loomba R., Sanyal A.J., et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015; 385: 956–65.

25. Argo C.K., Patrie J.T., Lackner C., et al. Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. J Hepatol. 2015; 62: 190–7.

26. Athyros V.G., Tziomalos K., Gossios T.D., et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Randomized Controlled Trial. Lancet. 2010; 376 (9756): 1916–22. DOI: https://doi.org/10.1016/S 0140-6736(10)61272-X

27. Browning J.D. Statins and hepatic steatosis: perspectives from the Dallas Heart Study. Hepatology. 2006; 44 (2): 466–71.

28. Lindor K.D., Kowdley K.V., Heathcote E.J., et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology. 2004; 39 (3): 770–8. DOI: https://doi.org/10.1002/hep.20092

29. Dufour J.F., Oneta C.M., Gonvers J.J., et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2006; 4 (12): 1537–43. DOI: https://doi.org/10.1016/j.cgh.2006.09.025

30. Tkacheva O.N., Zorina S.A., Khaibulina E.T., etc. Diabetic autonomic neuropathy: prevalence, pathogenesis, treatment. RMZh [Russian Medical Journal]. 2005; (20): 1329–33. (in Russian)

31. Tkacheva O.N., Vertkin A.L. Diabetic autonomic neuropathy. A guide for physicians. Moscow: GEOTAR-Media, 2009: 176 p. (in Russian)

32. Rahmanabadi A., Mahboob S., Amirkhizi F. et al. Oral α-lipoic acid supplementation in patients with non-alcoholic fatty liver disease: effects on adipokines and liver histology features. Randomized controlled trial. Food Funct. 2019; 10 (8): 4941–52. DOI: https://doi.org/10.1039/c9fo00449a

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)